Why Crinetics Pharmaceuticals (CRNX) Is Up 6.8% After FDA Approval of First Oral Acromegaly Therapy

• Crinetics Pharmaceuticals announced in late September that the U.S. Food and Drug Administration (FDA) approved PALSONIFY (paltusotine) as the first once-daily, oral treatment for adults with acromegaly who have had inadequate response to surgery or cannot undergo surgery.
• This approval sets a new standard for acromegaly care based on positive Phase 3 trial data and introduces a much-needed oral alternative to injectable therapies.
• We’ll explore how PALSONIFY’s unique oral delivery positions Crinetics Pharmaceuticals at the forefront of innovation in endocrinology.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Crinetics Pharmaceuticals' Investment Narrative?

To be a shareholder in Crinetics Pharmaceuticals, you have to believe in the company’s capacity to turn significant regulatory achievements into commercial momentum and sustainable growth, even while operating at a loss. The recent FDA approval of PALSONIFY as a first-line, once-daily oral therapy for acromegaly is a material catalyst that could change the risk profile and short-term focus of Crinetics. This milestone, validating the core pipeline, addresses an unmet need and may accelerate revenue growth, yet commercial execution and uptake are immediate questions for investors. Prior to the approval, risks centered largely on regulatory setbacks and capital requirements, but as the drug launches, attention shifts to how quickly PALSONIFY gains market traction and whether it can help offset substantial ongoing losses. The lack of profitability and prior shareholder dilution remain points to watch as the story develops.

But even with regulatory wins, the challenge of scaling sales and achieving profitability is far from over. Crinetics Pharmaceuticals' shares are on the way up, but they could be overextended by 16%. Uncover the fair value now.

Exploring Other Perspectives

Across three fair value estimates from the Simply Wall St Community, targets for Crinetics range from just US$8.51 to a very large US$1,085.69 per share. This spread reflects markedly different views on potential returns, particularly as the new PALSONIFY approval may shift both risk and reward for future performance. Consider exploring these varied outlooks to understand why opinions can differ so widely.

Explore 3 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be a potential multi-bagger!

Build Your Own Crinetics Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com